PDE9-IN-1

Research use only, not for human use.

PDE9-IN-1 is a potent, selective, and orally bioavailable Inhibitor of phosphodiesterase-9A (PDE9A)(IC50 of 8.7 nM).

PDE9-IN-1 is a potent, selective, and orally bioavailable Inhibitor of phosphodiesterase-9A (PDE9A)(IC50 of 8.7 nM).(In Vivo):In the Unilateral common carotid artery occlusion (UCCAO) mouse model, PDE9-IN-1 (2.5-5.0 mg/kg; orally) significantly reduces the day 6 escape latency time, increases the frequency of platform area crossings, and recoveres learning and memory function. High dose group possibly improved the escape latency time of mice.

PDE9-IN-1 is excellent selectivity across PDE families.

PDE9-IN-1 (2.5 and 5.0 mg/kg; Oral administration; daily for 21 days) effectively recovers learning and memory function. Animal Model:Unilateral common carotid artery occlusion (UCCAO) mouse model Dosage:2.5 and 5.0 mg/kg Administration:Oral administration; daily for 21 days Result:Significantly reduced the day 6 escape latency time and increased the frequency of platform area crossings, and recovered learning and memory function. High dose group possibly improved the escape latency time of mice.

——

Others

Other Targets

NMDA receptor

——

——

2305087-92-5

362.409

C17H23FN6O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (275.94 mM)

C[C@@H](Nc1nc2n(ncc2c(=O)[nH]1)C1CCCC1)C(=O)N1CC[C@H](F)C1

——

(-20℃)

With Ice Pack

≥ 2 years